Data Mining Strategies Applied in Brain Injury Models

  • Stefania MondelloEmail author
  • Firas Kobeissy
  • Isaac Fingers
  • Zhiqun Zhang
  • Ronald L. Hayes
  • Kevin K. W. Wang
Part of the Springer Optimization and Its Applications book series (SOIA, volume 65)


Traumatic brain injury or traumatic head injury is characterized as a direct physical impact or trauma to the head, causing brain injury. It represents a major national health problem without a US Food and Drug Administration-approved therapy. The application of neuroproteomics/neurogenomics has revolutionized the characterization of protein/gene dynamics, leading to a greater understanding of post-injury biochemistry. Neuroproteomics and Neurogenomics fields have undertaken major advances in the area of neurotrauma research focusing on biomarker identification. Several candidate markers have been identified and are being evaluated for their efficacy as biological biomarkers utilizing these “omics approaches”. The identification of these differentially expressed candidate markers using these techniques is proving to be only the first step in the biomarker development process. However, to translate these findings into the clinic, data-driven development cycle incorporating data-mining steps for discovery, qualification, verification, and clinical validation is needed. Data mining steps extend beyond the collected data level into an integrated scheme of animal modeling, instrumentation, and functional data analysis. In this chapter, we provide an introductory review of data-mining/systems biology coupled approaches that have been applied to biomarker discovery and clinical validation; in addition, the need for strengthening the integral roles of these disciplines in establishing a comprehensive understanding of specific brain disorder and biomarker identification in general.


Traumatic Brain Injury Brain Injury Severe Traumatic Brain Injury Clinical Validation Pretest Probability 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    A. Albert. On the use and computation of likelihood ratios in clinical chemistry. Clinical chemistry, 28(5):1113, 1982.Google Scholar
  2. 2.
    D.G. Altman. Practical statistics for medical research. Chapman & Hall/CRC, 1991.Google Scholar
  3. 3.
    K. Batchelder and P. Miller. A change in the marketinvesting in diagnostics. Nature biotechnology, 24(8):922–926, 2006.CrossRefGoogle Scholar
  4. 4.
    Pedro Beltrao, Christina Kiel, and Luis Serrano. Structures in systems biology. Current Opinion in Structural Biology, 17(3):378 – 384, 2007.CrossRefGoogle Scholar
  5. 5.
    P.M. Bossuyt, J.B. Reitsma, D.E. Bruns, C.A. Gatsonis, P.P. Glasziou, L.M. Irwig, D. Moher, D. Rennie, H.C.W. de Vet, and J.G. Lijmer. The stard statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clinical Chemistry, 49(1):7, 2003.Google Scholar
  6. 6.
    F. Campagne, S. Neves, CW Chang, L. Skrabanek, P.T. Ram, R. Iyengar, and H. Weinstein. Quantitative information management for the biochemical computation of cellular networks. Science’s STKE: signal transduction knowledge environment, 2004(248):pl11, 2004.Google Scholar
  7. 7.
    S.S. Chen, W.E. Haskins, A.K. Ottens, R.L. Hayes, N. Denslow, and K.K.W. Wang. Bioinformatics for traumatic brain injury: Proteomic data mining. Data Mining in Biomedicine, pages 363–387, 2007.Google Scholar
  8. 8.
    A. Cornish-Bowden, PJ Hunter, AA Cuellar, ED Mjolsness, NS Juty, S. Dronov, K. Takahashi, Y. Nakayama, ED Gilles, JL Kasberger, et al. The systems biology markup language (sbml): a medium for representation and exchange of biochemical network models. Bioinformatics, 19(4):524–531, 2003.Google Scholar
  9. 9.
    N. Denslow, M.E. Michel, M.D. Temple, C.Y. Hsu, K. Saatman, and R.L. Hayes. Application of proteomics technology to the field of neurotrauma. Journal of neurotrauma, 20(5):401–407, 2003.CrossRefGoogle Scholar
  10. 10.
    Q. Ding, Z. Wu, Y. Guo, C. Zhao, Y. Jia, F. Kong, B. Chen, H. Wang, S. Xiong, H. Que, et al. Proteome analysis of up-regulated proteins in the rat spinal cord induced by transection injury. Proteomics, 6(2):505–518, 2006.CrossRefGoogle Scholar
  11. 11.
    TJ Fagan. Letter: Nomogram for bayes theorem. The New England journal of medicine, 293(5):257, 1975.Google Scholar
  12. 12.
    S.G.N. Grant. Systems biology in neuroscience: bridging genes to cognition. Current opinion in neurobiology, 13(5):577–582, 2003.MathSciNetCrossRefGoogle Scholar
  13. 13.
    S.G.N. Grant and W.P. Blackstock. Proteomics in neuroscience: from protein to network. The Journal of Neuroscience, 21(21):8315, 2001.Google Scholar
  14. 14.
    T. Katano, T. Mabuchi, E. Okuda-Ashitaka, N. Inagaki, T. Kinumi, and S. Ito. Proteomic identification of a novel isoform of collapsin response mediator protein-2 in spinal nerves peripheral to dorsal root ganglia. Proteomics, 6(22):6085–6094, 2006.CrossRefGoogle Scholar
  15. 15.
    F.H. Kobeissy, S. Sadasivan, M.W. Oli, G. Robinson, S.F. Larner, Z. Zhang, R.L. Hayes, and K.K.W. Wang. Neuroproteomics and systems biology-based discovery of protein biomarkers for traumatic brain injury and clinical validation. PROTEOMICS–Clinical Applications, 2(10–11):1467–1483, 2008.Google Scholar
  16. 16.
    A.I.R. Maas, N. Stocchetti, and R. Bullock. Moderate and severe traumatic brain injury in adults. The Lancet Neurology, 7(8):728–741, 2008.CrossRefGoogle Scholar
  17. 17.
    S. Mondello, S.A. Robicsek, A. Gabrielli, G.M. Brophy, L. Papa, J. Tepas III, C. Robertson, A. Buki, D. Scharf, M. Jixiang, et al. αii-spectrin breakdown products (sbdps): Diagnosis and outcome in severe traumatic brain injury patients. Journal of Neurotrauma, 27(7):1203–1213, 2010.CrossRefGoogle Scholar
  18. 18.
    G.D. Murray, D. Barer, S. Choi, H. Fernandes, B. Gregson, K.R. Lees, A.I.R. Maas, A. Marmarou, A.D. Mendelow, E.W. Steyerberg, et al. Design and analysis of phase iii trials with ordered outcome scales: the concept of the sliding dichotomy. Journal of neurotrauma, 22(5):511–517, 2005.CrossRefGoogle Scholar
  19. 19.
    D. Nickerson and P. Hunter. Using cellml in computational models of multiscale physiology. In Engineering in Medicine and Biology Society, 2005. IEEE-EMBS 2005. 27th Annual International Conference of the, pages 6096–6099. IEEE, 2005.Google Scholar
  20. 20.
    N. Nogoy. Neuroproteomics: the hunt for biomarkers of neurotrauma. andrew ottens talks to nicole nogoy. Expert review of proteomics, 4(3):343, 2007.Google Scholar
  21. 21.
    N.A. Obuchowski, M.L. Lieber, and F.H. Wians Jr. Roc curves in clinical chemistry: uses, misuses, and possible solutions. Clinical chemistry, 50(7):1118, 2004.Google Scholar
  22. 22.
    S. Okie. Traumatic brain injury in the war zone. N Engl J Med, 352(20):2043–2047, 2005.CrossRefGoogle Scholar
  23. 23.
    A.K. Ottens, F.H. Kobeissy, B.F. Fuller, M. Chen Liu, M.W. Oli, R.L. Hayes, and K.K.W. Wang. Novel neuroproteomic approaches to studying traumatic brain injury. Progress in Brain Research, 161:401–418, 2007.CrossRefGoogle Scholar
  24. 24.
    A.K. Ottens, F.H. Kobeissy, E.C. Golden, Z. Zhang, W.E. Haskins, S.S. Chen, R.L. Hayes, KK Wang, and N.D. Denslow. Neuroproteomics in neurotrauma. Mass spectrometry reviews, 25(3):380–408, 2006.Google Scholar
  25. 25.
    V. Ozdemir, B. Williams-Jones, S.J. Glatt, M.T. Tsuang, J.B. Lohr, and C. Reist. Shifting emphasis from pharmacogenomics to theragnostics. Nature, 200:6.Google Scholar
  26. 26.
    J.A. Pineda, S.B. Lewis, A.B. Valadka, L. Papa, H.J. Hannay, S.C. Heaton, J.A. Demery, M.C. Liu, J.M. Aikman, V. Akle, et al. Clinical significance of α ii-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. Journal of neurotrauma, 24(2):354–366, 2007.CrossRefGoogle Scholar
  27. 27.
    J.B. Redell, Y. Liu, and P.K. Dash. Traumatic brain injury alters expression of hippocampal micrornas: potential regulators of multiple pathophysiological processes. Journal of neuroscience research, 87(6):1435–1448, 2009.CrossRefGoogle Scholar
  28. 28.
    N. Rifai, M.A. Gillette, and S.A. Carr. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nature biotechnology, 24(8):971–983, 2006.CrossRefGoogle Scholar
  29. 29.
    K.E. Saatman, A.C. Duhaime, R. Bullock, A.I.R. Maas, A. Valadka, and G.T. Manley. Classification of traumatic brain injury for targeted therapies. Journal of neurotrauma, 25(7):719–738, 2008.CrossRefGoogle Scholar
  30. 30.
    JA Wagner, SA Williams, and CJ Webster. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clinical Pharmacology & Therapeutics, 81(1):104–107, 2007.CrossRefGoogle Scholar
  31. 31.
    K.K.W. Wang, S.F. Larner, G. Robinson, and R.L. Hayes. Neuroprotection targets after traumatic brain injury. Current opinion in neurology, 19(6):514, 2006.Google Scholar
  32. 32.
    K.K.W. Wang, A.K. Ottens, M.C. Liu, S.B. Lewis, C. Meegan, M.W. Oli, F.C. Tortella, and R.L. Hayes. Proteomic identification of biomarkers of traumatic brain injury. Expert review of proteomics, 2(4):603–614, 2005.CrossRefGoogle Scholar
  33. 33.
    G. Zoroya. Scientists: brain injuries from war worse than thought. USA Today, 2007.Google Scholar
  34. 34.
    M.H. Zweig and G. Campbell. Receiver-operating characteristic (roc) plots: a fundamental evaluation tool in clinical medicine. Clin Chem, 39(4):561–577, 1993.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Stefania Mondello
    • 1
    Email author
  • Firas Kobeissy
    • 1
  • Isaac Fingers
    • 1
  • Zhiqun Zhang
    • 1
  • Ronald L. Hayes
    • 1
  • Kevin K. W. Wang
    • 1
  1. 1.Banyan BiomarkersAlachuaUSA

Personalised recommendations